Affimed Formed a Research Collaboration with Genentech for Novel NK Cells

 Affimed Formed a Research Collaboration with Genentech for Novel NK Cells

Affimed Formed a Research Collaboration with Genentech for Novel NK Cells

Shots:
  • The collaboration is for development and commercialization of novel NK cell engager-based immunotherapeutics to treat multiple cancers
  •  Affimed’s will use its ROCK platform (Redirected Optimized Cell Killing) to develop NK cell and T cell-engaging Abs and Genentech will take care of all global clinical development and commercialization
  •  Affimed to receive an upfront $96M and additional payment of up to $5.0B including specified development, regulatory and commercial milestones with royalties on sales, with expected closure in Q3’18

Click here to read full press release/ article | Ref: Affimed | Image:  Sec filling

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post